The Danish pharmaceutical company said Thursday that the acquisition will expand its portfolio of projects and intellectual property rights in the diabetes and obesity segments and help expand Novo Nordisk’s research presence in the United States.
Calibrium, launched in 2013, focuses on the discovery and early development of novel peptides for the treatment of diabetes and related metabolic diseases. Formed last year, MB2 is a clinical-stage biopharma company advancing a pipeline of first-in-class, mixed agonist drugs for diabetes and obesity.
“We are always on the lookout for ways to strengthen our leadership position within therapeutic proteins,” stated Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk. “This research team has demonstrated world-class capabilities in protein design and created a project portfolio of innovative product leads that fit very well with our aspirations within diabetes and obesity.”
Financial terms of the acquisition deal weren’t disclosed. Pending U.S. regulatory approval, the transaction is expected to close in the third quarter of this year.
“It’s an honor to join the global Novo Nordisk research community. Their intense focus on metabolic diseases, which over the years has led to numerous breakthrough protein-based medicines, aligns perfectly with my career-long priorities,” commented Richard DiMarchi, chief scientific officer and co-founder of Calibrium and MB2. “I’m optimistic that together we can create novel, transformative therapies in the fight against the global epidemic of diabetes and obesity.”